A molecular signature predictive of indolent prostate cancer

Science Translational Medicine

Volumn 5, Issue 202, 2013, Pages

  Irshad, Shazia ^a,d   Bansal, Mukesh ^a   Castillo Martin, Mireia ^b   Zheng, Tian ^a,c   Aytes, Alvaro ^a   Wenske, Sven ^a   Le Magnen, Clémentine ^a   Guarnieri, Paolo ^a   Sumazin, Pavel ^a   Benson, Mitchell C ^a   Shen, Michael M ^a   Califano, Andrea ^a   Abate Shen, Cory ^a  

^a NewYork Presbyterian Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CDKN1A GENE; CELL PROLIFERATION; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; CONTROLLED STUDY; FGFR1 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLEASON SCORE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; ONCOGENE; PMP22 GENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; VALIDATION PROCESS;

AGED; AGING; ANIMALS; DECISION TREES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SPECIES SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884684430     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006408     Document Type: Article

References (61)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. M. R. Cooperberg, J. M. Broering, P. W. Kantoff, P. R. Carroll, Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J. Urol. 178, S14-S19 (2007).
3. H. G. Welch, P. C. Albertsen, Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl. Cancer Inst. 101, 1325-1329 (2009).
4. J. R. Prensner, M. A. Rubin, J. T. Wei, A. M. Chinnaiyan, Beyond PSA: The next generation of prostate cancer biomarkers. Sci. Transl. Med. 4, 127rv3 (2012).
5. D. F. Gleason, Histologic grading of prostate cancer: A perspective. Hum. Pathol. 23, 273-279 (1992).
6. T. J. Wilt, R. MacDonald, I. Rutks, T. A. Shamliyan, B. C. Taylor, R. L. Kane, Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann. Intern. Med. 148, 435-448 (2008).
7. T. J. Daskivich, K. Chamie, L. Kwan, J. Labo, R. Palvolgyi, A. Dash, S. Greenfield, M. S. Litwin, Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 117, 2058-2066 (2011).
8. H. G. Welch, W. C. Black, Overdiagnosis in cancer. J. Natl. Cancer Inst. 102, 605-613 (2010).
9. B. B. Cantrell, D. P. DeKlerk, J. C. Eggleston, J. K. Boitnott, P. C. Walsh, Pathological factors that influence prognosis in stage A prostatic cancer: The influence of extent versus grade. J. Urol. 125, 516-520 (1981).
10. M. R. Cooperberg, P. R. Carroll, L. Klotz, Active surveillance for prostate cancer: Progress and promise. J. Clin. Oncol. 29, 3669-3676 (2011).
11. J. H. Hayes, D. A. Ollendorf, S. D. Pearson, M. J. Barry, P. W. Kantoff, S. T. Stewart, V. Bhatnagar, C. J. Sweeney, J. E. Stahl, P. M. McMahon, Active surveillance compared with initial treatment for men with low-risk prostate cancer: A decision analysis. JAMA 304, 2373-2380 (2010).
12. J. J. Tosoian, B. J. Trock, P. Landis, Z. Feng, J. I. Epstein, A. W. Partin, P. C. Walsh, H. B. Carter, Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J. Clin. Oncol. 29, 2185-2190 (2011).
13. M. M. Shen, C. Abate-Shen, Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24, 1967-2000 (2010).
14. B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E.Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers, W. L. Gerald, Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
15. M. Narita, S. W. Lowe, Senescence comes of age. Nat. Med. 11, 920-922 (2005).
16. J. Campisi, Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120, 513-522 (2005).
17. J. Campisi, Aging, tumor suppression and cancer: High wire-act! Mech. Ageing Dev. 126, 51-58 (2005).
18. M. Collado, M. A. Blasco, M. Serrano, Cellular senescence in cancer and aging. Cell 130, 223-233 (2007).
19. J. Choi, I. Shendrik, M. Peacocke, D. Peehl, R. Buttyan, E. F. Ikeguchi, A. E. Katz, M. C. Benson, Expression of senescence-associated β-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 56, 160-166 (2000).
20. P. Castro, D. Giri, D. Lamb, M. Ittmann, Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55, 30-38 (2003).
21. Z. Chen, L. C. Trotman, D. Shaffer, H. K. Lin, Z. A. Dotan, M. Niki, J. A. Koutcher, H. I. Scher, T. Ludwig, W. Gerald, C. Cordon-Cardo, P. P. Pandolfi, Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
22. J. P. de Magalhães, J. Curado, G. M. Church, Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics 25, 875-881 (2009).
23. P. Wirapati, C. Sotiriou, S. Kunkel, P. Farmer, S. Pradervand, B. Haibe-Kains, C. Desmedt, M. Ignatiadis, T. Sengstag, F. Schütz, D. R. Goldstein, M. Piccart, M. Delorenzi, Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
24. J. Cuzick, G. P. Swanson, G. Fisher, A. R. Brothman, D. M. Berney, J. E. Reid, D. Mesher, V. O. Speights, E. Stankiewicz, C. S. Foster, H. Møller, P. Scardino, J. D. Warren, J. Park, A. Younus, D. D. Flake II, S. Wagner, G. Gutin, J. S. Lanchbury, S. Stone; Transatlantic Prostate Group, Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 12, 245-255 (2011).
25. Y. P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, G. Michalopoulos, M. Becich, J. H. Luo, Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790-2799 (2004).
26. A. Bhattacharjee, W. G. Richards, J. Staunton, C. Li, S. Monti, P. Vasa, C. Ladd, J. Beheshti, R. Bueno, M. Gillette, M. Loda, G. Weber, E. J. Mark, E. S. Lander, W. Wong, B. E. Johnson, T. R. Golub, D. J. Sugarbaker, M. Meyerson, Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U.S.A. 98, 13790-13795 (2001).
27. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
28. R. Bhatia-Gaur, A. A. Donjacour, P. J. Sciavolino, M. Kim, N. Desai, P. Young, C. R. Norton, T. Gridley, R. D. Cardiff, G. R. Cunha, C. Abate-Shen, M. M. Shen, Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977 (1999).
29. M. J. Kim, R. Bhatia-Gaur, W. A. Banach-Petrosky, N. Desai, Y. Wang, S. W. Hayward, G. R. Cunha, R. D. Cardiff, M. M. Shen, C. Abate-Shen, Nkx3.1 mutantmice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62, 2999-3004 (2002).
30. C. Abate-Shen, M. M. Shen, E. Gelmann, Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76, 717-727 (2008).
31. X. Ouyang, T. L. DeWeese, W. G. Nelson, C. Abate-Shen, Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. 65, 6773-6779 (2005).
32. A. G. Sowalsky, H. Ye, G. J. Bubley, S. P. Balk, Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res. 73, 1050-1055 (2013).
33. A. Sboner, F. Demichelis, S. Calza, Y. Pawitan, S. R. Setlur, Y. Hoshida, S. Perner, H. O. Adami, K. Fall, L. A. Mucci, P. W. Kantoff, M. Stampfer, S. O. Andersson, E. Varenhorst, J. E. Johansson, M. B. Gerstein, T. R. Golub, M. A. Rubin, O. Andrén, Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med. Genomics 3, 8 (2010).
34. A. V. D'Amico, R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank, G. A. Broderick, J. E. Tomaszewski, A. A. Renshaw, I. Kaplan, C. J. Beard, A. Wein, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969-974 (1998).
35. P. Motamedinia, J. L. RiChard, J. M. McKiernan, G. J. DeCastro, M. C. Benson, Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance. Urology 80, 1070-1074 (2012).
36. J. Campisi, Cancer and ageing: Rival demons? Nat. Rev. Cancer 3, 339-349 (2003).
37. S. Roy, R. P. Singh, C. Agarwal, S. Siriwardana, R. Sclafani, R. Agarwal, Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 7, 1828-1835 (2008).
38. T. Abbas, A. Dutta, p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 9, 400-414 (2009).
39. V. D. Acevedo, M. Ittmann, D. M. Spencer, Paths of FGFR-driven tumorigenesis. Cell Cycle 8, 580-588 (2009).
40. N. Turner, R. Grose, Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 10, 116-129 (2010).
41. F. Yang, Y. Zhang, S. J. Ressler, M. M. Ittmann, G. E. Ayala, T. D. Dang, F. Wang, D. R. Rowley, FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 73, 3716-3724 (2013).
42. J. Edwards, N. S. Krishna, C. J. Witton, J. M. Bartlett, Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin. Cancer Res. 9, 5271-5281 (2003).
43. G. Meyer Zu Hörste, K. A. Nave, Animal models of inherited neuropathies. Curr. Opin. Neurol. 19, 464-473 (2006).
44. K. Adlkofer, R. Martini, A. Aguzzi, J. Zielasek, K. V. Toyka, U. Suter, Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat. Genet. 11, 274-280 (1995).
45. U. Suter, G. J. Snipes, Peripheral myelin protein 22: Facts and hypotheses. J. Neurosci. Res. 40, 145-151 (1995).
46. Z. Ding, C. J. Wu, G. C. Chu, Y. Xiao, D. Ho, J. Zhang, S. R. Perry, E. S. Labrot, X. Wu, R. Lis, Y. Hoshida, D. Hiller, B. Hu, S. Jiang, H. Zheng, A. H. Stegh, K. L. Scott, S. Signoretti, N. Bardeesy, Y. A. Wang, D. E. Hill, T. R. Golub, M. J. Stampfer, W. H. Wong, M. Loda, L. Mucci, L. Chin, R. A. DePinho, SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
47. E. K. Markert, H. Mizuno, A. Vazquez, A. J. Levine, Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. U.S.A. 108, 21276-21281 (2011).
48. S. A. Tomlins, S. M. Aubin, J. Siddiqui, R. J. Lonigro, L. Sefton-Miller, S. Miick, S. Williamsen, P. Hodge, J. Meinke, A. Blase, Y. Penabella, J. R. Day, R. Varambally, B. Han, D. Wood, L. Wang, M. G. Sanda, M. A. Rubin, D. R. Rhodes, B. Hollenbeck, K. Sakamoto, J. L. Silberstein, Y. Fradet, J. B. Amberson, S. Meyers, N. Palanisamy, H. Rittenhouse, J. T. Wei, J. Groskopf, A. M. Chinnaiyan, Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3, 94ra72 (2011).
49. D. Olmos, D. Brewer, J. Clark, D. C. Danila, C. Parker, G. Attard, M. Fleisher, A. H. Reid, E. Castro, S. K. Sandhu, L. Barwell, N. B. Oommen, S. Carreira, C. G. Drake, R. Jones, C. S. Cooper, H. I. Scher, J. S. de Bono, Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: A prospective, two-stage study. Lancet Oncol. 13, 1114-1124 (2012).
50. M. Braig, S. Lee, C. Loddenkemper, C. Rudolph, A. H. Peters, B. Schlegelberger, H. Stein, B. Dörken, T. Jenuwein, C. A. Schmitt, Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
51. M. Collado, J. Gil, A. Efeyan, C. Guerra, A. J. Schuhmacher, M. Barradas, A. Benguría, A. Zaballos, J. M. Flores, M. Barbacid, D. Beach, M. Serrano, Tumour biology: Senescence in premalignant tumours. Nature 436, 642 (2005).
52. M. Malumbres, I. Pérez De Castro, M. I. Hernández, M. Jiménez, T. Corral, A. Pellicer, Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15INK4b. Mol. Cell. Biol. 20, 2915-2925 (2000).
53. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
54. M. J. Pencina, R. B. D'Agostino,Overall C as ameasure of discrimination in survival analysis:Model specific population value and confidence interval estimation. Stat. Med. 23, 2109-2123 (2004).
55. M. S. Schröder, A. C. Culhane, J. Quackenbush, B. Haibe-Kains, survcomp: An R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 27, 3206-3208 (2011).
56. P. Grambsch, T. Therneau, Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515-526 (1994).
57. R. A. Irizarry, B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, T. P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
58. Z. Wu, R. Irizarry, R. Gentleman, F. M. Murillo, F. Spencer, A model-based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc. 99, 909-917 (2004).
59. V. K. Mootha, C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, M. J. Daly, N. Patterson, J. P. Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J. N. Hirschhorn, D. Altshuler, L. C. Groop, PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
60. G. A. F. Seber, Multivariate Observations (John Wiley & Sons Inc., Hoboken, NJ, 1984).
61. C. W. Kinkade, M. Castillo-Martin, A. Puzio-Kuter, J. Yan, T. H. Foster, H. Gao, Y. Sun, X. Ouyang, W. L. Gerald, C. Cordon-Cardo, C. Abate-Shen, Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118, 3051-3064 (2008).